Brazil approves new generics

The Brazilian Regulatory Agency ANVISA has approved two new generics containing active substances for which there were no competitors on the market. This measure assures that doctors and patients may access new cheaper treatment options, as the two generics will enter the market with a 35% discount compared to the originator. The first product is an analgesic agent containing remifentanil hydrochloride used to induce or maintain anaesthesia during surgery, and in the analgesia and sedation of patients on respiratory devices in intensive care units. The second is the generic version of a medicinal product containing propafenone hydrochloride, indicated in the treatment of cardiac rhythm alterations. Both products are interchangeable with the corresponding reference products.